Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06172751
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2023-12-07
Brief Title:
TrinetX Study of Hypereosinophilic Syndrome HES Without an Identifiable Non-haematological Secondary Cause
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
TrinetX Study of Hypereosinophilic Syndrome HES Without an Identifiable Non-haematological Secondary Cause
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to build the knowledge base on clinical characteristics clinical management and treatment outcomes of HES
Detailed Description:
Retrospective database analysis using TriNetX database to describe HES patient characteristics journey and disease burden
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None